Glofitamab/Obinutuzumab

PreclinicalMonoclonal antibody

Bristol-Myers Squibb

Glofitamab/Obinutuzumab is one of 34 small molecule programs targeting Lymphoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Relapsed/refractory Non-Hodgkin LymphomaRecruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Relapsed/refractory Non-Hodgkin LymphomaPreclinical

Recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

EEastern Cooperative Oncology Group

Preclinical

15 2

Zofran

Novartis

Preclinical

2 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Systemic Therapy

1 8

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 9

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

2 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Relapsed/refractory Non-Hodgkin Lymphoma

NCT06090539

Clinical

Trials by Indication[1]

Relapsed/Refractory Non-Hodgkin Lymphoma1 trial

A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT06090539·460 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Glofitamab/Obinutuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glofitamab/Obinutuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glofitamab/Obinutuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Preclinical[1]
Company: Bristol-Myers Squibb

Glofitamab/Obinutuzumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Relapsed/Refractory Non-Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News